The applying from Lykos — a drug corporation incubated from the Multidisciplinary Affiliation for Psychedelic Scientific tests, or MAPS — arrived within the FDA less than a cloud of controversy. Previous trial individuals experienced alleged adverse gatherings weren't noted — which include feelings of suicidality following the procedure — a